Acasti Pharma (Grace Therapeutics) posted a Q1 2026 net loss of $3.4M as it submitted an NDA for GTx-104, its IV nimodipine formulation for aSAH. Cash balance was $20M, with a cash runway expected through at least the next 12 months and potentially into Q2 2027 with warrant exercises.

Grace Therapeutics posted a net income for Q4 2025 despite no revenue, mainly due to favorable changes in derivative warrant liabilities and tax benefits. The company highlighted progress on its GTx-104 NDA and secured $15M in funding, supporting its near-term goals.

Grace Therapeutics reported a net loss of $4.2 million, or $0.36 per share, for the quarter ended December 31, 2024. The company announced positive topline data from its Phase 3 STRIVE-ON safety trial and secured up to $30 million in gross proceeds from a private placement financing.

Grace Therapeutics reported a net loss of $3.4 million, or $0.30 per share for the quarter ended September 30, 2024. The company completed enrollment of its Phase 3 STRIVE-ON safety trial and rebranded to Grace Therapeutics.

Acasti Pharma reported a net loss of $12.9 million for the year ended March 31, 2024. The company's cash and cash equivalents totaled $23.0 million at the end of the fiscal year, which is expected to support operations into the second calendar quarter of 2026.

Acasti Pharma reported a net loss of $2.4 million for the quarter ended December 31, 2023, a decrease of $1.5 million compared to the same period in 2022. The company is focused on its GTX-104 program and the STRIVE-ON Phase 3 trial, with patient enrollment ongoing. Acasti's cash runway is projected to extend into the second calendar quarter of 2026.

Acasti Pharma reported a net loss of $3.3 million, or $0.43 per share, for the quarter ended September 30, 2023. The company highlighted the initiation of its Phase 3 STRIVE-ON trial and secured $7.5 million in private placement financing.

Acasti Pharma reported a net loss of $3.9 million for the third quarter ended December 31, 2022, with $31.3 million in cash, cash equivalents, and short-term investments.

Acasti Pharma reported a net loss of $4.9 million, or $0.11 loss per share, for the second quarter ended September 30, 2022. The company's cash, cash equivalents and short-term investments totaled $34.9 million as of September 30, 2022.

Acasti Pharma reported a net loss of $3.8 million, or $0.09 per share, for the third quarter of fiscal 2022, compared to a net loss of $3.2 million, or $0.26 per share, for the same period in 2020. The company's research and development expenses increased due to the new clinical assets acquired in the merger with Grace Therapeutics, Inc. The company had cash, cash equivalents and short-term investments of $46.3 million as of December 31, 2021.

Acasti Pharma reported having $50.8 million in cash, cash equivalents and short-term investments as of September 30, 2021, and completed a merger with Grace Therapeutics. Subject enrollment has commenced for a pivotal PK bridging study for GTX-104. Four composition of matter patents granted for GTX-101 and GTX-102.